Evidence map›Paper›PMID 40828354›Full record

SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026

Prognostic significance of systemic immune-inflammation index in hepatocellular carcinoma: a meta-analysis.

Zhi Li, Juan Luo, Lihua Peng, Bangqiang Wu, Zebo Yu

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhi Li *Clinical Laboratory, Affiliated Zigong TCM Hospital of Chengdu University of TCM, No.1000, Longhui South Street, Ziliujing District, Zigong, 643010, Sichuan, China.
Juan Luo *Clinical Laboratory, Ziliujing District People's Hospital, Zigong, 643036, Sichuan, China.
Lihua PengClinical Laboratory, Affiliated Zigong TCM Hospital of Chengdu University of TCM, No.1000, Longhui South Street, Ziliujing District, Zigong, 643010, Sichuan, China.
Bangqiang WuDepartment of Hematology and Oncology, Affiliated Zigong TCM Hospital of Chengdu University of TCM, Zigong, 643010, Sichuan, China.
Zebo YuClinical Laboratory, Affiliated Zigong TCM Hospital of Chengdu University of TCM, No.1000, Longhui South Street, Ziliujing District, Zigong, 643010, Sichuan, China. Yzb13980223845@163.com.ORCID http://orcid.org/0009-0007-0950-2196

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEmerging evidence suggests an association between the systemic immune-inflammation index (SII) and the survival outcomes of individuals with hepatocellular carcinoma (HCC). However, existing research findings are inconsistent, and no definitive conclusions have been reached. This research aimed to explore the predictive accuracy of the SII in patients with HCC.

methodsNumerous databases, encompassing PubMed, Embase, Web of Science, and Cochrane Library, were thoroughly retrieved from the database inception until January 14, 2025, to identify studies on the correlation between SII and survival outcomes in HCC. Studies were screened according to pre-established eligibility criteria. The primary endpoints included overall survival (OS), recurrence-free survival (RFS), and progression-free survival (PFS), which were appraised via hazard ratios (HRs) with corresponding 95% confidence intervals (CIs).

results39 high-quality cohort studies involving 47 comparison groups were included in this analysis. As proven by the aggregated data, increased SII was significantly linked to shorter OS (HR = 1.64, 95% CI: 1.45-1.85; p < 0.00001), RFS (HR = 1.68, 95% CI: 1.44-1.96; p < 0.00001), and PFS (HR = 1.48, 95% CI: 1.20-1.82; p = 0.0002) in individuals with HCC. Furthermore, subgroup analyses revealed that age, region, intervention strategy, and SII thresholds affected the validity of SII for predicting the prognosis of HCC.

conclusionIn HCC patients treated with monotherapy or combination therapy, a higher SII before treatment is significantly associated with shorter OS, RFS, and PFS. SII may serve as an important biological indicator for assessing the prognosis of HCC, providing a critical reference for the scientific and systematic treatment of HCC.

Indexed as

Carcinoma, HepatocellularInflammationLiver NeoplasmsHumansPrognosisProgression-Free SurvivalHepatocellular carcinomaInflammatory biomarkersMeta-analysisPrognostic significance of survivalSIISystemic immune-inflammation index

Identifiers

PMID40828354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.